Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48520 | 0.80 | CA12 (0.50) | PAOXPOLBCA12CA2CA9 | |
| SCHEMBL15223814 | 0.76 | USP2 (0.53) | PAOXCA12CA2CA9LMNA | |
| SCHEMBL15836016 | 0.75 | POLB (0.33) | POLBLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL15223813 | 0.75 | KDM4E (0.40) | PAOXPOLBLMNAUSP2KDM4E | |
| SCHEMBL14017913 | 0.74 | ALDH1A1 (0.45) | PAOXPOLBCA12CA2CA9 | |
| SCHEMBL48345 | 0.71 | ALDH1A1 (0.62) | POLBCA12CA2CA9ALOX15 | |
| SCHEMBL10883164 | 0.71 | USP2 (0.56) | PAOXCA12CA9LMNAUSP2 | |
| SCHEMBL20374850 | 0.71 | CA12 (0.37) | PAOXPOLBCA12CA2CA9 | |
| SCHEMBL6750857 | 0.71 | ALDH1A1 (0.38) | POLBALDH1A1KMT2AMAPT | |
| SCHEMBL15030933 | 0.71 | POLB (0.39) | POLBCA12CA2CA9USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3092010-B1 | METHOD FOR PURIFYING CYS-LINKED ANTIBODY-DRUG CONJUGATES | SYNTHON BIOPHARMACEUTICALS BV (NL) | 2018-07-11 | — | — | EP | disclosed |
| US-20160324979-A1 | METHOD FOR PURIFYING CYS-LINKED ANTIBODY-DRUG CONJUGATES | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324979-A1 | METHOD FOR PURIFYING CYS-LINKED ANTIBODY-DRUG CONJUGATES | SLC3A2, FCGR3B, CD44 | PAOX 4430/4885POLB 3718/4885CA12 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.